Health & Fitness
Thu, March 8, 2012Wed, March 7, 2012Tue, March 6, 2012Mon, March 5, 2012Fri, March 2, 2012Thu, March 1, 2012Wed, February 29, 2012Tue, February 28, 2012Mon, February 27, 2012Sat, February 25, 2012Fri, February 24, 2012Pharmacyclics to Host a Conference Call on March 15, 2012 to Discuss Second Quarter Fiscal 2012 Financial and Operational Resul
Published in Health and Fitness on Thursday, March 1st 2012 at 16:56 GMT by Market Wire
Pharmacyclics to Host a Conference Call on March 15, 2012 to Discuss... -- SUNNYVALE, Calif., March 1, 2012 /PRNewswire/ --
Pharmacyclics to Host a Conference Call on March 15, 2012 to Discuss Second Quarter Fiscal 2012 Financial and Operational Results
SUNNYVALE, Calif., March 1, 2012 /PRNewswire/ -- Pharmacyclics, Inc. (NASDAQ: [ PCYC ]), a biopharmaceutical company focused on developing and commercializing innovative small molecule drugs for the treatment of cancer and immune mediated diseases, today announced that senior management will host a conference call on Thursday, March 15th, at 1:30 pm PST to discuss the company's second quarter fiscal 2012 financial and operational results as previously announced.
Conference Call Details: |
|
Date: Thursday March 15, 2012 |
Time: 1:30 pm PST |
Listen via Internet: [ http://ir.pharmacyclics.com/events.cfm ] |
Toll-free: +1-877-407-8133 |
International: +1-201-689-8040 |
The webcast replay will be available for 30 days on the Investor Relations section of the company's Web site at [ www.pharmacyclics.com ].
About Pharmacyclics
Pharmacyclics® is a clinical-stage biopharmaceutical company focused on developing and commercializing innovative small-molecule drugs for the treatment of cancer and immune mediated diseases. Our mission and goal is to build a viable biopharmaceutical company that designs, develops and commercializes novel therapies intended to improve quality of life, increase duration of life and resolve serious unmet medial healthcare needs; and to identify promising product candidates based on scientific development expertise, develop our products in a rapid, cost-efficient manner and pursue commercialization and/or development partners when and where appropriate.
Presently, Pharmacyclics has three product candidates in clinical development and several preclinical molecules in lead optimization. We are committed to high standards of ethics, scientific rigor, and operational efficiency as we move each of these programs to viable commercialization.
The Company is headquartered in Sunnyvale, California and is listed on NASDAQ under the symbol PCYC. To learn more about how Pharmacyclics advances science to improve human healthcare visit us at [ http://www.pharmacyclics.com ].
SOURCE Pharmacyclics, Inc.
[ Back to top ] RELATED LINKS
[ http://www.pharmacyclics.com ]
